Revenio Group OyjCHIX:REG1VH 76 ROA % is 6.69% as of Mar. 2026, which is 53% below its 10-year median of 14.33. GuruFocus rates CHIX:REG1VH with a GF Score™ of 76/100 and a GF Value™ of €40.41. The stock has 2 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Revenio Group Oyj ranks better than 89.26% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Revenio Group Oyj's annualizedNet Income for the quarter that ended in Mar. 2026 was €10.0 Mil.
Revenio Group Oyj's average Total Assets over the quarter that ended in Mar. 2026 was €149.4 Mil. Therefore, Revenio Group Oyj's annualized ROA % for the quarter that ended in Mar. 2026 was 6.69%.
The historical rank and industry rank for Revenio Group Oyj's ROA % or its related term are showing as below:
CHIX:REG1Vh'
s ROA % Range Over the Past 10 Years
Min: 11.04 Med: 14.33 Max: 39.4
Current: 11.04
During the past 13 years, Revenio Group Oyj's highest ROA % was 39.40%. The lowest was 11.04%. And the median was 14.33%.
CHIX:REG1Vh's ROA % is ranked better than 89.26% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.54
vs CHIX:REG1Vh: 11.04
Revenio Group Oyj (CHIX:REG1Vh) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Revenio Group Oyj ROA % Related Terms
Revenio Group Oyj ROA % Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Revenio Group Oyj's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's ROA % distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Revenio Group Oyj (CHIX:REG1VH) has a ROA % of 6.69% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Revenio Group Oyj and its competitors. This is 53% below median its historical median of 14.33. Over the past decade, Revenio Group Oyj's ROA % has ranged from 11.04 to 39.40. According to the industry distribution chart, Revenio Group Oyj ranks #92 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 10.7%.
Is Revenio Group Oyj's ROA % too high?
Revenio Group Oyj's current ROA % of 6.69% is 53% below median its 10-year median of 14.33. Over the past 10 years, this metric has ranged from a low of 11.04 to a high of 39.40. The Medical Devices & Instruments industry median ROA % is 0.54. Revenio Group Oyj's value of 6.69% is 1138.9% above this industry median. Based on the distribution chart, Revenio Group Oyj ranks #92 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Revenio Group Oyj has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #92 out of 857 companies for ROA %. This places Revenio Group Oyj in the top 11% of its industry — outperforming the majority of peers. The industry median ROA % is 0.54. Revenio Group Oyj's value of 6.69% is 1138.9% above this benchmark. Historically, Revenio Group Oyj's own ROA % has ranged from 11.04 to 39.40 over the past decade. While the company's 10-year median is 14.33 vs. the industry median of 0.54, Revenio Group Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.54, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current ROA % of 6.69% is 1138.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current ROA % is 6.69%, which is 53% below median its own 10-year median of 14.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Revenio Group Oyj (CHIX:REG1VH) has a current ROA % of 6.69%. The stock's GF Value™ is €40.41, compared to a current price of €16.47 — trading 59.2% below its estimated fair value. The current ROA % is 6.69%, which is 53% below median its 10-year median of 14.33 and 1138.9% above the Medical Devices & Instruments industry median of 0.54. Revenio Group Oyj's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Revenio Group Oyj (CHIX:REG1VH), the current ROA % is 6.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (CHIX:REG1VH) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of €16.47 is trading 59.2% below its estimated GF Value™ of €40.41.
Key valuation signals for CHIX:REG1VH:
ROA %: 6.69% (53% below median its 10-year median of 14.33)
GF Value™: €40.41 vs. price of €16.47 (59.2% below fair value)
Industry Position: 1138.9% above the Medical Devices & Instruments median (#92 of 857)
No single metric tells the full story. See the CHIX:REG1VH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
76GF Score
Get the complete analysis for CHIX:REG1VH
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:REG1VH has been successfully added to your 
